parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.11 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in neutrophils	0.75
chemistry Open Targets	compounds already reach it: resatorvid, eritoran tetrasodium, eritoran	0.90
trials ClinicalTrials.gov	5 Parkinson's trials, 0 stopped	1.00
literature PubMed	335 Parkinson's papers of 37,855	0.23
pathways Reactome	18 pathways; mostly immune signalling	0.90

No case: the score is under the bar. Receipt 2372

receipt 2380: TLR4 in dopamine neurons, braak

power: full sample +0.08 (p 0.767, n 18), 95% CI -0.41 to +0.52. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.12 (p 0.627, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.07 (p 0.787, n 18). could be the mix.
skeptic: leave-one-out range -0.04 to +0.21, sign flips 2; without severely affected donors +0.08 (p 0.767, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TLR4 in dopamine neurons.

case closed: nothing better to follow up.

receipt 2379: TLR4 in astrocytes, braak

power: full sample -0.11 (p 0.664, n 18), 95% CI -0.55 to +0.38. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.06 (p 0.807, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.03 (p 0.901, n 18). could be the mix.
skeptic: leave-one-out range -0.20 to +0.03, sign flips 2; without severely affected donors -0.11 (p 0.664, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TLR4 in astrocytes.

case closed: nothing better to follow up.

loading the receipts